



- ❖ A. E. Fohnera et al., PharmGKB summary: very important pharmacogene information for ABCG2. *Pharmacogenet Genomics*, 2017.
- ❖ V. Leduc et al., Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia. *Pharmacogenet Genomics*, 2016.
- ❖ D. Baldassarre et al., Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety. *G. Ital. Arterioscler.*, 2013.
- ❖ DF. Carr et al., SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. *Clinical Pharmacology & Therapeutics*, 2013.
- ❖ M. K. DeGorter et al., Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care. *Circ. Cardiovasc. Genet.*, 2013.
- ❖ L. Elens et al., CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. *Pharmacogenomics*, 2012.
- ❖ D. Wang et al., Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics Journal*, 2011.